Free Trial
NASDAQ:CNSP

CNS Pharmaceuticals (CNSP) Stock Price, News & Analysis

CNS Pharmaceuticals logo
$3.28 +0.39 (+13.49%)
As of 02:07 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About CNS Pharmaceuticals Stock (NASDAQ:CNSP)

Advanced

Key Stats

Today's Range
$2.96
▼
$3.26
50-Day Range
$2.99
▼
$5.94
52-Week Range
$1.90
▼
$10.54
Volume
17,027 shs
Average Volume
424,505 shs
Market Capitalization
$4.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Sell

Company Overview

CNS Pharmaceuticals is a biopharmaceutical company focused on developing treatments for cancers of the brain and central nervous system. Its research has centered on investigational therapies intended to address the challenges of treating tumors that affect these areas.

The company’s lead candidate has been berubicin, an experimental anthracycline designed to cross the blood-brain barrier. CNS Pharmaceuticals has evaluated berubicin for glioblastoma, an aggressive form of brain cancer. The drug remains investigational and is not an approved treatment.

The company has also pursued other experimental compounds for brain and central nervous system conditions. Its work has included clinical development and research; it does not market an established portfolio of approved medicines.

AI Generated. May Contain Errors.

CNS Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
17th Percentile Overall Score

CNSP MarketRank™: 
0.852995758215 of 5 stars

CNS Pharmaceuticals scored higher than 17% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    CNS Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    CNS Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about CNS Pharmaceuticals' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of CNS Pharmaceuticals is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of CNS Pharmaceuticals is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    CNS Pharmaceuticals has a P/B Ratio of 0.45. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about CNS Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    0.11% of the float of CNS Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    CNS Pharmaceuticals has a short interest ratio ("days to cover") of 0.07, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in CNS Pharmaceuticals has recently increased by 26.00%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    CNS Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    CNS Pharmaceuticals does not have a long track record of dividend growth.

  • News Sentiment

    CNS Pharmaceuticals has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for CNS Pharmaceuticals this week, compared to 1 article on an average week.
  • MarketBeat Follows

    1 people have added CNS Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, CNS Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    1.82% of the stock of CNS Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    14.02% of the stock of CNS Pharmaceuticals is held by institutions.

  • Read more about CNS Pharmaceuticals' insider trading history.
Receive CNSP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CNS Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CNSP Stock News Headlines

Management just bought 2.8 million shares
Management just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 in one quarter. Institutions own about 83% of shares, including BlackRock's 32 million shares worth $716 million and Vanguard's 48 million shares worth nearly $1.1 billion. A new multi-year deal with Palantir adds an AI-driven edge to this energy producer's operations.tc pixel
See More Headlines

CNSP Stock Analysis - Frequently Asked Questions

CNS Pharmaceuticals' stock was trading at $5.25 at the beginning of 2026. Since then, CNSP shares have decreased by 37.6% and is now trading at $3.2780.

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) announced its quarterly earnings data on Monday, November, 16th. The company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.03.

Shares of CNS Pharmaceuticals reverse split on Friday, February 21st 2025.The 1-50 reverse split was announced on Wednesday, February 19th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 20th 2025. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

CNS Pharmaceuticals (CNSP) raised $10 million in an initial public offering on Friday, November 8th 2019. The company issued 2,125,000 shares at $4.00-$5.00 per share. Benchmark acted as the underwriter for the IPO.

Shares of CNSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that CNS Pharmaceuticals investors own include NIO (NIO), Palantir Technologies (PLTR), Plug Power (PLUG), Intel (INTC), NVIDIA (NVDA), Novavax (NVAX) and Advanced Micro Devices (AMD).

Company Calendar

Today
11/16/2026
Last Earnings
11/16/2026
Next Earnings (Estimated)
11/16/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:CNSP
CIK
1729427
Fax
N/A
Employees
8
Year Founded
2017

Profitability

EPS (Trailing Twelve Months)
($23.59)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$15.85 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-204.25%
Return on Assets
-141.87%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.86
Quick Ratio
5.86

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.29 per share
Price / Book
0.45

Miscellaneous

Outstanding Shares
1,460,000
Free Float
1,434,000
Market Cap
$4.79 million
Optionable
Not Optionable
Beta
3.21

Social Links

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

This page (NASDAQ:CNSP) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners